Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Who is this study for? Adult patients with attention deficit hyperactivity disorder
What treatments are being studied? Immediate-release Methylphenidate
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• White Brazilian of European descent
• Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
• Eligibility to immediate-release MPH (IR-MPH) treatment
Locations
Other Locations
Brazil
Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre
RECRUITING
Porto Alegre
Contact Information
Primary
Eugênio H Grevet, MD, PhD
ehgrevet@gmail.com
+55 51 3359-8094
Backup
Claiton HD Bau, MD, PhD
claiton.bau@gmail.com
+55 51 33086718
Time Frame
Start Date: 2002-02
Estimated Completion Date: 2032-12
Participants
Target number of participants: 600
Treatments
Experimental: IR-MPH
Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
Related Therapeutic Areas
Sponsors
Collaborators: Federal University of Rio Grande do Sul, Coordination for the Improvement of Higher Education Personnel, Conselho Nacional de Desenvolvimento Científico e Tecnológico
Leads: Hospital de Clinicas de Porto Alegre